[
  {
    "ts": "2025-12-31T01:15:07+00:00",
    "headline": "Dow Jones Futures: Market Near Highs As New Year Looms; Eli Lilly, Shopify Forge Buy Points",
    "summary": "The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-2025-new-year-eli-lilly-shopify-buy-points/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "df58b2a7-2039-3fdb-a6ac-e94e6367fb4e",
      "content": {
        "id": "df58b2a7-2039-3fdb-a6ac-e94e6367fb4e",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Market Near Highs As New Year Looms; Eli Lilly, Shopify Forge Buy Points",
        "description": "",
        "summary": "The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.",
        "pubDate": "2025-12-31T01:15:07Z",
        "displayTime": "2025-12-31T01:15:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/df58b2a7-2039-3fdb-a6ac-e94e6367fb4e/dow-jones-futures-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/d1342cd9c9006d22e66388ec54401cd1",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T7jRcLqHxhXdnEl7TG0czA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/d1342cd9c9006d22e66388ec54401cd1.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QIety7dQeLaKcZW.1bPm4w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/d1342cd9c9006d22e66388ec54401cd1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-2025-new-year-eli-lilly-shopify-buy-points/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SHOP"
            },
            {
              "symbol": "APH"
            },
            {
              "symbol": "FTAI"
            },
            {
              "symbol": "FTAIM"
            },
            {
              "symbol": "FTAIN"
            },
            {
              "symbol": "RDDT"
            },
            {
              "symbol": "NU"
            },
            {
              "symbol": "EVER"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T12:41:44+00:00",
    "headline": "Dow Jones Futures Fall On 2025's Final Day; Eli Lilly, Shopify Forge Buy Points",
    "summary": "The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-2025-new-year-eli-lilly-shopify-buy-points/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "df58b2a7-2039-3fdb-a6ac-e94e6367fb4e",
      "content": {
        "id": "df58b2a7-2039-3fdb-a6ac-e94e6367fb4e",
        "contentType": "STORY",
        "title": "Dow Jones Futures Fall On 2025's Final Day; Eli Lilly, Shopify Forge Buy Points",
        "description": "",
        "summary": "The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.",
        "pubDate": "2025-12-31T12:41:44Z",
        "displayTime": "2025-12-31T12:41:44Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/df58b2a7-2039-3fdb-a6ac-e94e6367fb4e/dow-jones-futures-fall-on.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/d1342cd9c9006d22e66388ec54401cd1",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T7jRcLqHxhXdnEl7TG0czA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/d1342cd9c9006d22e66388ec54401cd1.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QIety7dQeLaKcZW.1bPm4w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/d1342cd9c9006d22e66388ec54401cd1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-2025-new-year-eli-lilly-shopify-buy-points/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SHOP"
            },
            {
              "symbol": "APH"
            },
            {
              "symbol": "EVR"
            },
            {
              "symbol": "RDDT"
            },
            {
              "symbol": "NU"
            },
            {
              "symbol": "FTAI"
            },
            {
              "symbol": "FTAIM"
            },
            {
              "symbol": "FTAIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T12:36:00+00:00",
    "headline": "VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains",
    "summary": "Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.",
    "url": "https://finance.yahoo.com/news/vnda-obtains-fda-nod-motion-123600036.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4e9beb83-30ec-35b0-8d41-af0ecd3eb782",
      "content": {
        "id": "4e9beb83-30ec-35b0-8d41-af0ecd3eb782",
        "contentType": "STORY",
        "title": "VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains",
        "description": "",
        "summary": "Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.",
        "pubDate": "2025-12-31T12:36:00Z",
        "displayTime": "2025-12-31T12:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d7sHwZPFV1U3B4BGoNlXfg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k5CBlnqEqKxZI1S0BuG_ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vnda-obtains-fda-nod-motion-123600036.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vnda-obtains-fda-nod-motion-123600036.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VNDA"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T14:34:42+00:00",
    "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
    "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
    "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "60f9e371-cf5c-34d8-8971-8c8928c120be",
      "content": {
        "id": "60f9e371-cf5c-34d8-8971-8c8928c120be",
        "contentType": "STORY",
        "title": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
        "description": "",
        "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
        "pubDate": "2025-12-31T14:34:42Z",
        "displayTime": "2025-12-31T14:34:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vu.kxzmN7yCA.wz8Cs.cHg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Brb0J12XOUXl4lathAg3vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T16:20:00+00:00",
    "headline": "Could This Potential Move Boost Eli Lilly's Prospects?",
    "summary": "The stock already looks unstoppable, and this move won't hurt its momentum.",
    "url": "https://www.fool.com/investing/2025/12/31/could-this-potential-move-boost-eli-lillys-prospec/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a869f710-2fed-3ed5-9a63-cad8330fe55a",
      "content": {
        "id": "a869f710-2fed-3ed5-9a63-cad8330fe55a",
        "contentType": "STORY",
        "title": "Could This Potential Move Boost Eli Lilly's Prospects?",
        "description": "",
        "summary": "The stock already looks unstoppable, and this move won't hurt its momentum.",
        "pubDate": "2025-12-31T16:20:00Z",
        "displayTime": "2025-12-31T16:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/15ef6a9b6e9b2a6f099b4f9e6cf4a301",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Physician shaking businessperson's hand. ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UcJPM3mQ7jmLa51OgN0Cbw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/15ef6a9b6e9b2a6f099b4f9e6cf4a301.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bp94QMVCWSYejJvg5uXsJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/15ef6a9b6e9b2a6f099b4f9e6cf4a301.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/31/could-this-potential-move-boost-eli-lillys-prospec/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/could-potential-move-boost-eli-162000624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T16:03:01+00:00",
    "headline": "Pfizer and GSK Lead 2026 U.S. Drug Price Hikes",
    "summary": "Drugmakers Brace for January Price Changes",
    "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-2026-u-160301390.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "8756a28c-f1e5-3ca8-b81b-b694c1bb0bac",
      "content": {
        "id": "8756a28c-f1e5-3ca8-b81b-b694c1bb0bac",
        "contentType": "STORY",
        "title": "Pfizer and GSK Lead 2026 U.S. Drug Price Hikes",
        "description": "",
        "summary": "Drugmakers Brace for January Price Changes",
        "pubDate": "2025-12-31T16:03:01Z",
        "displayTime": "2025-12-31T16:03:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vu.kxzmN7yCA.wz8Cs.cHg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Brb0J12XOUXl4lathAg3vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-2026-u-160301390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-2026-u-160301390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T15:57:18+00:00",
    "headline": "Vanda Jumps 21% After FDA Approves Motion Sickness Therapy",
    "summary": "FDA approves Vanda's Nereus, developed with Eli Lilly, supported by three pivotal clinical trials.",
    "url": "https://finance.yahoo.com/news/vanda-jumps-21-fda-approves-155718225.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "b49babf3-9fd3-3743-a06b-35b00caf30c6",
      "content": {
        "id": "b49babf3-9fd3-3743-a06b-35b00caf30c6",
        "contentType": "STORY",
        "title": "Vanda Jumps 21% After FDA Approves Motion Sickness Therapy",
        "description": "",
        "summary": "FDA approves Vanda's Nereus, developed with Eli Lilly, supported by three pivotal clinical trials.",
        "pubDate": "2025-12-31T15:57:18Z",
        "displayTime": "2025-12-31T15:57:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/a6466d29bef0b789fc9d773b3359e284",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s9SqeJ8eQgcqKzIcJbBnWw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a6466d29bef0b789fc9d773b3359e284.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xm04wmD_w.NV44Lfo61u5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a6466d29bef0b789fc9d773b3359e284.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vanda-jumps-21-fda-approves-155718225.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vanda-jumps-21-fda-approves-155718225.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VNDA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T15:57:00+00:00",
    "headline": "Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval",
    "summary": "The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.",
    "url": "https://www.barrons.com/articles/vanda-pharmaceuticals-stock-jumps-motion-sickness-drug-approval-516c2fa4?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "86dce327-4952-397f-ad93-2e1162febc69",
      "content": {
        "id": "86dce327-4952-397f-ad93-2e1162febc69",
        "contentType": "STORY",
        "title": "Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval",
        "description": "",
        "summary": "The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.",
        "pubDate": "2025-12-31T15:57:00Z",
        "displayTime": "2025-12-31T15:57:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/86dce327-4952-397f-ad93-2e1162febc69/vanda-pharmaceuticals-shares.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/7718f67cb1e2ac1420687a8d0269bb5e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BlaH.e0sL07G6yBEIN5lhw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/7718f67cb1e2ac1420687a8d0269bb5e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NmUEYltJFUYpBU87Ba_suQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/7718f67cb1e2ac1420687a8d0269bb5e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/vanda-pharmaceuticals-stock-jumps-motion-sickness-drug-approval-516c2fa4?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VNDA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T20:06:35+00:00",
    "headline": "So Long, Warren. Buffett Leaves Astonishing Gains As He Steps Down As CEO.",
    "summary": "Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion.",
    "url": "https://www.investors.com/news/warren-buffett-berkshire-hathaway-brkb-stock/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e2a3e841-2b86-3267-aba8-1c3e9cf2a74d",
      "content": {
        "id": "e2a3e841-2b86-3267-aba8-1c3e9cf2a74d",
        "contentType": "STORY",
        "title": "So Long, Warren. Buffett Leaves Astonishing Gains As He Steps Down As CEO.",
        "description": "",
        "summary": "Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion.",
        "pubDate": "2025-12-31T20:06:35Z",
        "displayTime": "2025-12-31T20:06:35Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e2a3e841-2b86-3267-aba8-1c3e9cf2a74d/so-long-warren-buffett.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f9e572c8a1caf838183ed40f221bcf79",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mt8nFMTbvRyBMlLA1QFxXA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f9e572c8a1caf838183ed40f221bcf79.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xTwfCuBkjW2guyhzK.048Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f9e572c8a1caf838183ed40f221bcf79.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/warren-buffett-berkshire-hathaway-brkb-stock/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BRK.A"
            },
            {
              "symbol": "BRKB"
            },
            {
              "symbol": "BRKA"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "GOOG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T20:08:00+00:00",
    "headline": "In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s",
    "summary": "Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold for years.",
    "url": "https://www.barrons.com/articles/eli-lilly-stock-weight-loss-pill-glp-1-lead-f023d84f?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "933ad83b-f1f4-32d2-b2c6-ec15a0004415",
      "content": {
        "id": "933ad83b-f1f4-32d2-b2c6-ec15a0004415",
        "contentType": "STORY",
        "title": "In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s",
        "description": "",
        "summary": "Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold for years.",
        "pubDate": "2025-12-31T20:08:00Z",
        "displayTime": "2025-12-31T20:08:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/933ad83b-f1f4-32d2-b2c6-ec15a0004415/in-the-year-of-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/57830fabe2a4a744de0c3be1599a6486",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w.wgZMXjNvZhZ6RvZHendA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/57830fabe2a4a744de0c3be1599a6486.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AtIWrqEDTI0rUxUffwwVSA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/57830fabe2a4a744de0c3be1599a6486.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/eli-lilly-stock-weight-loss-pill-glp-1-lead-f023d84f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T15:28:00+00:00",
    "headline": "Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake",
    "summary": "With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.",
    "url": "https://www.marketbeat.com/originals/why-wall-street-gave-up-on-pfizerand-why-that-may-be-a-mistake/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "697cd6c1-86c6-34d5-8c4e-c8d8724a3b10",
      "content": {
        "id": "697cd6c1-86c6-34d5-8c4e-c8d8724a3b10",
        "contentType": "STORY",
        "title": "Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake",
        "description": "",
        "summary": "With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.",
        "pubDate": "2025-12-31T15:28:00Z",
        "displayTime": "2025-12-31T15:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/a82ecbb8d33ef1b499b4a7b411928b86",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Pfizer research laboratory with branded display and vaccine vials, illustrating a major pharmaceutical company rebuilding value and pipeline strength.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4vTdyP1QI9_UKlQEofKPwQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/a82ecbb8d33ef1b499b4a7b411928b86.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N1iH5NYlV0hlbc5BuicF6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/a82ecbb8d33ef1b499b4a7b411928b86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/why-wall-street-gave-up-on-pfizerand-why-that-may-be-a-mistake/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-wall-street-gave-pfizer-152800660.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T22:05:00+00:00",
    "headline": "FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026",
    "summary": "Novo Nordisk is down big in 2025, but hope is far from lost in 2026. The company's newly approved weight-loss pill could be the remedy that shares need.",
    "url": "https://www.marketbeat.com/originals/fda-approves-novo-nordisks-wegovy-pill-a-game-changer-for-2026/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "6231365e-7e0f-3410-9900-b26e1622406b",
      "content": {
        "id": "6231365e-7e0f-3410-9900-b26e1622406b",
        "contentType": "STORY",
        "title": "FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026",
        "description": "",
        "summary": "Novo Nordisk is down big in 2025, but hope is far from lost in 2026. The company's newly approved weight-loss pill could be the remedy that shares need.",
        "pubDate": "2025-12-31T22:05:00Z",
        "displayTime": "2025-12-31T22:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/5ee1ce539428b25d132662ec12eac56c",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Imaginative depiction of Novo Nordisk campus, as a hand holds a bottle of weight loss pills, highlighting GLP-1 drug innovation.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TiEpnBTpCLWnKC_l4ujiDw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/5ee1ce539428b25d132662ec12eac56c.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LzHy7Irkez1zvp_t3uoySQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/5ee1ce539428b25d132662ec12eac56c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/fda-approves-novo-nordisks-wegovy-pill-a-game-changer-for-2026/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-novo-nordisks-wegovy-220500876.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]